How to cover Novartis’ $475K CAR-T drug Kymriah? A ‘new payment model’ is the only way, Express Scripts saysadmin 22nd September 2017 Uncategorised 0
Steve Miller, the chief medical officer of Express Scripts, is one of the loudest voices in the ongoing debate over high drug prices, so it was only a matter of time before he weighed in on Kymriah, Novartis’ $475,000 CAR-T treatment for some patients with leukemia. That time came yesterday, and Miller didn’t mince words in his assessment of the new product’s price.
More: How to cover Novartis’ 5K CAR-T drug Kymriah? A ‘new payment model’ is the only way, Express Scripts says